INVESTOR RELATIONS
Company Reports filed with the SEC
Form 8-K current report disclosing beneficial ownership of production building valued at $2,045,209 and supply agreement for complete vial production line
Form S-4/A registration statement for the merger of Nika BioTechnology, Inc. into Nika Pharmaceuticals as filed with the SEC on April 5, 2024
Form 10-K annual report with audited financial statements for the period ending December 31, 2023 as filed with the SEC on April 1, 2024
Form 4 statement of changes of beneficial ownership for Dimitar Slavchev Savov as filed with the SEC on March 19, 2024
Form 4 statement of changes of beneficial ownership for Clifford Paul Redekop as filed with the SEC on March 19, 2024
Form S-4 registration statement for the merger of Nika BioTechnology, Inc. into Nika Pharmaceuticals as filed with the SEC on March 6, 2024
Form 8-K current report disclosing the merger between NKPH and NIKA as filed with the SEC on April 1, 2024
Form 8-K current report disclosing change in auditors as filed with the SEC on February 16, 2024
Form 10-Q periodic report for the period ending on September 30, 2023 as filed with the SEC on October 31, 2023
Form 8-K current report providing additional Form 10 information as filed with the SEC on September 18, 2023
Form 10-Q periodic report for the period ending June 30, 2023 as filed with the SEC on August 21, 2023
Form 10-Q periodic report for the period ending March 31, 2023 as filed with the SEC on May 15, 2023
Form 10-K annual report with audited financial statements for the period ending December 31, 2022 as filed with the SEC on April 10, 2023
Form 8-K current report announcing Dr. Darena Zlateva as the company’s Chief Science Officer as filed with the SEC on November 12, 2022
Form 10-Q periodic report for the period ending September 30, 2022 as filed with the SEC on November 10, 2022
Form 10-Q/A periodic report for the period ending June 30, 2022 as filed with the SEC on November 7, 2022
Form 8-K current report disclosing change in auditors as filed with the SEC on November 1, 2022
Form 8-K current report for name change and changes in Bylaws and Articles of Incorporation as filed with the SEC on August 22, 2022
Form 10-Q periodic report for the period ending March 31, 2022 as filed with the SEC on May 12, 2023
Form 8-K current report disclosing the acquistion of exclusive rights for TNG, Physiolong, and Carotilen, change in shell status, and designation of right for Preferred stock as filed with the SEC on April 12, 2022
Form 8-K current report disclosing change in control and appointment of Dimitar Savov and Clifford Redekop as company officers and directors as filed with the SEC on April 5, 2022
Form 10-K annual report with audited financial statements for the period ending December 31, 2021 as filed with the SEC on March 3, 2022
Form 10-Q periodic report for the period ending September 30, 2021 as filed with the SEC on November 12, 2021
Form 10-Q periodic report for the period ending June 30, 2021 as filed with the SEC on August 11, 2021
Form 10-Q periodic report for the period ending March 31, 2021 as filed with the SEC on May 13, 2021
Form 10-K/A amended annual report with audited financial statements for the period ending December 31, 2020 as filed with the SEC on March 25, 2022
Form 10-12G/A amended securities registration containing Form 10 as filed with the SEC on January 21, 2021